IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label federal drug administration. Show all posts
Showing posts with label federal drug administration. Show all posts
Thursday, 11 December 2025

Teva Pharmaceuticals will remove over 200 improper patent listings from the Orange Book

›
On December 10, 2025, the FTC announced that Teva Pharmaceuticals will “[r]emove. . .  Over 200 Improper Patent Listings” to improve generic...
›
Home
View web version
Powered by Blogger.